MEDS Synthetic Control Arms & Synthetic Control Data

White Paper

De-risk Go/No Go Product Development Decisions by Reusing Patient Trial Data

Precision Medicine promises better, longer lasting tumor control and outcomes, representing higher value. However, the challenge is clinical data interpretation and decision making in the absence of randomized controlled trials, which may not be feasible.

Learn how Medidata Synthetic Controls is enabling new insights for oncology clinical development and streamlines clinical development and mitigates Go/No-go decision risk. Synthetic Control Data can assist disease learning and future trial planning, and Synthetic Control Arm provides precise data for confident interpretation of uncontrolled trials.

Download this seven-page whitepaper today!